touchFEATURE

Extending overall survival and preserving quality of life in HR+/HER2- advanced breast cancer

Watch Time: 15 mins

This content is intended for healthcare professionals outside the USA only.

Please confirm that you are a healthcare professional outside the USA.

to access this content

This activity has been sponsored by Novartis AG. Novartis AG. provided financial support and video content, and has had input into the detailed project scope. This activity is provided by Touch Medical Communications (TMC) for touchONCOLOGY.

This content is intended for healthcare professionals outside the USA only

Please confirm that you are a healthcare professional outside the USA

Decline

This activity has been sponsored by Novartis AG. Novartis AG. provided financial support and video content, and has had input into the detailed project scope. This activity is provided by Touch Medical Communications (TMC) for touchONCOLOGY.

Prescribing Information

Breast Cancer View Time: 15 mins

touchFEATURE Extending overall survival and preserving quality of life in HR+/HER2- advanced breast cancer

Understand how new KISQALI® data demonstrates extended survival and quality of life benefits in HR+/HER2- advanced breast cancer.

 
Videos
From progression-free survival to overall survival with ribociclib

Previously, the MONALEESA studies reported prolonged progression free survival with ribociclib alongside endocrine therapy in women with HR+/HER2- advanced breast cancer.7 Now, the same studies have reported clinically and statistically significant prolongation in overall survival.9–11 Gabriel Hortobagyi, MD, from the University of Texas MD Anderson Cancer Center discusses the potential impact of these results in the treatment of advanced breast cancer.

Video content supplied by Novartis AG.

1/3 Next Chapter
 
Overall survival results from the phase III MONALEESA-2 study

The phase III MONALEESA-2 study showed that adding ribociclib to a backbone of letrozole results in statistically significant median overall survival (OS) of more than 5 years in postmenopausal patients with HR+/HER2- metastatic breast cancer.9 In this video, David Cameron, MD, from Edinburgh Cancer Research Centre discusses the impact of extending OS for his patients with advanced breast cancer and their families.9

Video content supplied by Novartis AG.

2/3 Next Chapter
 
Quality of life and chemotherapy-free survival in the MONALEESA studies

A pooled analysis of data from the three MONALEESA studies indicated quality of life benefits with ribociclib compared with endocrine therapy alone.12 Peter Fasching, MD, from the Comprehensive Cancer Center Erlangen-EMN, Germany, discusses the importance of maintaining quality of life for patients, in addition to improved survival.

Video content supplied by Novartis AG.

3/3 Leave Feedback
Leave Feedback
Overview & Learning Objectives
Overview

Cyclin-dependent kinases 4 and 6 (CDK4/6) play a key function in regulating cell cycle progression and have a known role in promoting cancer growth.1,2 Three orally available CDK4/6 inhibitors, including ribociclib (KISQALI®) are now available in Europe for people with HR+/HER2- advanced or metastatic breast cancer.3–8 Now, overall survival (OS) results have been reported from the phase III MONALEESA-2 trial, showing median OS beyond 5 years in postmenopausal patients with HR+/HER2- advanced breast cancer treated with ribociclib and endocrine therapy.9

Learning Objectives

After watching this activity, participants should be better able to:

  • Recognise the role of CDK4 versus CDK6 inhibition in metastatic breast cancer growth
  • Discuss the overall survival results from the MONALEESA-2 study and the potential impact for patients
  • Describe the quality of life benefits of ribociclib from a pooled analysis of the MONALEESA studies
References
References
  1. O'Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol. 2016;13(7):417–30.
  2. Hosford SR, Miller TW. Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. Pharmgenomics Pers Med. 2014;7:203–15.
  3. European Medicines Agency. Ibrance (palbociclib) European Public Assessment Report (EPAR). 2022. Available at: www.ema.europa.eu/en/medicines/human/EPAR/ibrance (accessed March 2022)
  4. European Medicines Agency. Verzenios (abemaciclib) EPAR. 2022. Available at: www.ema.europa.eu/en/medicines/human/EPAR/verzenios (accessed March 2022)
  5. European Medicines Agency. Kisqali (ribociclib) EPAR. 2021. Available at: www.ema.europa.eu/en/medicines/human/EPAR/kisqali (accessed March 2022)
  6. Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2- negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016; 17: 425–39.
  7. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375:1738–48.
  8. Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35:3638–46.
  9. Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386:942–50.
  10. Slamon DJ, Neven P, Chia S, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382(6):514–24.
  11. Lu YS, Im SA, Colleoni M, et al. Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+/HER2- advanced breast cancer in MONALEESA-7: A phase III randomized clinical trial. Clin Cancer Res. 2022;28(5):851–9.
  12. Fasching PA, Bardia A, Nusch A, et al. Pooled analysis of patient-reported quality of life in the MONALEESA-2, -3, and -7 trials of ribociclib plus endocrine therapy to treat hormone receptor–positive, HER2-negative advanced breast cancer. Ann Oncol. 2020;31(4_suppl). Abstract 2760.
Downloads

View and download resources from this activity to support your learning and share with colleagues

This content is intended for healthcare professionals only. Please confirm that you are a healthcare professional.

Accept Decline
Feedback Close
Feedback

Please provide feedback for this touchFEATURE on the following
(scale of 1-5 where 1=strongly disagree and 5=strongly agree):

Feedback Close
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72